Results 31 to 40 of about 5,674 (178)

Validated Reversed-Phase Liquid Chromatographic Method with Gradient Elution for Simultaneous Determination of the Antiviral Agents: Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in Their Dosage Forms

Molecules, 2020
A simple, rapid, sensitive, and precise reversed-phase liquid chromatographic method was developed and validated for the simultaneous determination of four direct-acting antivirals, sofosbuvir (SF), ledipasvir (LD), declatasvir (DC), and simeprevir (SM),
Essam Ezzeldin, Nisreen F. Abo-Talib, Marwa H. Tammam, Yousif A. Asiri, Abd El-Galil E. Amr, Abdulrahman A. Almehizia   +5 more
doaj   +1 more source

Identification of resistance mutations to DAA's against Hepatitis C Virus in infected subjects in Mexico

Annals of Hepatology, 2022
Introduction and Objectives: Death due to liver damage caused by hepatitis C virus (HCV), this agent represents one of the most frequent health threats in Mexico.
K López-Riojas, KA Galán-Huerta, AF Ruiz-Higareda, L Muñoz-Espinosa, P Cordero-Pérez, D Arellanos-Soto, S Lozano-Sepúlveda, AM Rivas-Estilla   +7 more
doaj   +1 more source

Characteristics of patients completed sofosbuvir-daclatasvir treatment cascade (n = 184).

, 2021
Characteristics of patients completed sofosbuvir-daclatasvir treatment cascade (n = 184).
Kuntjoro Harimurti (10035887), Evy Yunihastuti (428215), Andri Sanityoso Sulaiman (10881067), Rahmat Hariyanto (11268731)   +3 more
core   +1 more source

Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety

Gut and Liver, 2018
Background/AimsThe treatment with daclatasvir plus asunaprevir (DCV+ASV) is associated with potent antiviral effects in patients with genotype 1b hepatitis C virus (HCV) infection.
Hye Won Lee, Se Rim Oh, Dong Yun Kim, Yechan Jeong, Seungtaek Kim, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jun Yong Park   +10 more
doaj   +1 more source

Efficacy and Adverse Effects of Sofosbuvir plus Daclatasvir Therapy in Chronic HCV Patients in Sharkia Governorate, Egypt [PDF]

Afro-Egyptian Journal of Infectious and Endemic Diseases, 2018
Background and study aim: Hepatitis C is the most pressing public health challenge in Egypt with variable prevalence rates among different age groups. This study aimed to detect the efficacy and adverse effects of sofosbuvir plus daclatasvir therapy in ...
Abeer abdelkader, Noha Shahin, Nahla El-Gammal   +2 more
doaj   +1 more source

Daclatasvir 30 mg/day is the correct dose for patients taking atazanavir/cobicistat [PDF]

, 2017
Contains fulltext : 169944.pdf (Publisher’s version ) (Open Access)BACKGROUND: Atazanavir is boosted with the cytochrome P450 (CYP) 3A4 inhibitor ritonavir.
Burger, D.M., Kanter, C.T.M.M. de, Smolders, E.J., Colbers, E.P.H., Velthoven-Graafland, K., Drenth, J.P.H., Smolders, E J, Colbers, E P H, de Kanter, C T M M, Burger, D M, Velthoven-Graafland, K, Drenth, J P H   +11 more
core   +1 more source

Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen

Kidney International Reports, 2017
There is paucity of data on sofosubvir (SOF)−based therapy in patients on maintenance hemodialysis (MHD). The objective of this report is to describe our experience using SOF-based direct antiviral agent (DAA) therapy in MHD patients in India.
Sanjay Kumar Agarwal, Soumita Bagchi, Raj Kumar Yadav   +2 more
doaj   +1 more source

Boletín CIME 02 : Daclatasvir [PDF]

, 2016
Publicaciones CIMEFil: Sola, Nancy. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas; Argentina.Este Boletín está estructurado con una introducción general del ingrediente farmacéutico activo daclatasvir, su aprobación en Argentina y la ...
Sola, Nancy
core   +1 more source

The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C

One Health & Risk Management, 2020
Introduction. Viral hepatitis C (HCV) is a significant global health problem. The risk of developing chronic HCV is up to 80% of patients, of whom 10-20% can develop liver cirrhosis or hepatocellular carcinoma which can lead to death.
Irina RUSU, Liliana HODOROGEA, Tiberiu HOLBAN   +2 more
doaj   +1 more source

Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection [PDF]

, 2022
BACKGROUND: The COVER trial evaluated whether nitazoxanide or sofosbuvir/daclatasvir could lower the risk of SARS-CoV-2 infection. Nitazoxanide was selected given its favourable pharmacokinetics and in vitro antiviral effects against SARS-CoV-2 ...
Johnstone, Hilary, Simmons, B, Sokhela, S, Hilary Johnstone, Joana Woods, Leah Ellis, Bosch, Bronwyn, Ellis, L, Andrew Owen, Owen, Andrew, Carmen Perez Casas, Johnstone, H, Hill, A, Casas, CP, Ellis, Leah, Woods, Joana, Bosch, B, Owen, A, Hill, Andrew, Simiso Sokhela, Woods, J, Willem Daniel Francois Venter, Bronwyn Bosch, Venter, WDF, Akpomiemie, Godspower, Bryony Simmons, Godspower Akpomiemie, Andrew Hill, Casas, Carmen Perez, Sokhela, Simiso, Venter, Willem Daniel Francois, Simmons, Bryony, Akpomiemie, G   +32 more
core   +1 more source